Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.

Decramer, Marc

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. [electronic resource] - The Lancet. Respiratory medicine Jun 2014 - 472-86 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

2213-2619

10.1016/S2213-2600(14)70065-7 doi


Administration, Inhalation
Aged
Benzyl Alcohols--administration & dosage
Bronchodilator Agents--administration & dosage
Chlorobenzenes--administration & dosage
Dose-Response Relationship, Drug
Double-Blind Method
Drug Combinations
Female
Follow-Up Studies
Forced Expiratory Volume--drug effects
Humans
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive--drug therapy
Quinuclidines--administration & dosage
Scopolamine Derivatives--administration & dosage
Time Factors
Tiotropium Bromide
Treatment Outcome